Clinical Trial

A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer

Name: A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer — clinical trial record (NCT07076095)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).

Trial Details

NCT Number	NCT07076095
Lead Sponsor	SUNHO（China）BioPharmaceutical CO., Ltd. Collaborators: Zhengzhou University
Conditions	Small Cell Lung Cancer
Enrollment	200 participants
Start Date	2025-08-01
Primary Completion	2028-08-01 (estimated)
Study Completion	2031-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-21